Patents by Inventor Zbigniew Janusz Witczak

Zbigniew Janusz Witczak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11590084
    Abstract: The present invention relates a microcapsule that comprises an active pharmaceutical ingredient and a polymeric shell comprised of polymeric materials such as polyether, polyester, polyamine, polyamide, polyurea, polyurethane, polythiocarbamate, and polythiocarbonate. The outer surface of shell comprises surface functional groups such as hydroxide, primary amine, carboxylic acid, or protected forms thereof. These surface functional groups may be reacted further with reactants to place specific organic groups on the surface of the microcapsule. Such microcapsules are prepared by a modified interfacial condensation polymerization.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: February 28, 2023
    Inventors: Roman Bielski, Zbigniew Janusz Witczak
  • Publication number: 20190125687
    Abstract: The present invention relates a microcapsule that comprises an active pharmaceutical ingredient and a polymeric shell comprised of polymeric materials such as polyether, polyester, polyamine, polyamide, polyurea, polyurethane, polythiocarbamate, and polythiocarbonate. The outer surface of shell comprises surface functional groups such as hydroxide, primary amine, carboxylic acid, or protected forms thereof. These surface functional groups may be reacted further with reactants to place specific organic groups on the surface of the microcapsule. Such microcapsules are prepared by a modified interfacial condensation polymerization.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 2, 2019
    Inventors: Roman BIELSKI, Zbigniew Janusz WITCZAK
  • Publication number: 20080050309
    Abstract: A pharmaceutical, wherein the formulation is a conjugate of a saccharide with one or a plurality of isotopic boron-10 atoms or gadolinium, and having a utility in the binary form of low energy neutron therapy (i.e. boron neutron capture therapy). Further, that the therapy has an indicated use for the selective targeting and killing of oxygenated and hypoxic cells in tumors, and that the pharmaceutical is preferentially taken up by cancer cells. The inclusion of any of a family of saccharides, its derivatives or analogues, including sulfur linkage saccharides as a delivery carrier for boron-10 atoms or the rare element gadolinium is a strategy to take advantage of the hallmark of cancer cells, that being an increased requisite for glucose to sustain a rate of uncontrollable cell division and proliferation. A cancer cell facilitates an increase in availability of molecular glucose by overexpression of glucose transporter proteins on membrane surfaces.
    Type: Application
    Filed: August 25, 2006
    Publication date: February 28, 2008
    Applicant: Hadron Systems
    Inventors: Zbigniew Janusz Witczak, Frederick William Fischer